Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Atrium Therapeutics earns $15M milestone from Bristol Myers Squibb for heart RNA therapy progress
BMY
$64.27
-$0.39 -0.60%

Atrium Therapeutics earns $15M milestone from Bristol Myers Squibb for heart RNA therapy progress

Company Fundamentals
13 Aug 2026
PRNewsWire
View Source
Bullish
pluang ai news

Atrium Therapeutics announced it received a $15 million milestone payment from Bristol Myers Squibb due to the successful delivery of a lead RNA therapeutic compound targeting a cardiology condition. This payment is part of their ongoing collaboration focused on developing RNA-based treatments for heart diseases, with potential total milestones reaching over $2 billion plus royalties. Atrium is advancing multiple RNA therapies for rare genetic heart diseases, including a clinical trial for ATR 1072. Bristol Myers Squibb will fund future development and commercialization efforts under the agreement.

More News (BMY)

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App